They are prepared by licensed compounding pharmacies to meet individual patient needs when commercially available options are not suitable for their personalized needs
Professor Phostle [edit] (French: Professeur Hippolyte Calys [7] Professor Decimus Phostle is an astronomer, observatory director, and expedition leader in The Shooting Star
What's Next: Orforglipron (oral GLP-1) completing Phase 3 trials with submissions expected by year-end 2025 CEO Dave Ricks expects FDA approval by March 2026 International launches accelerating in China, Brazil, India, and Mexico The GLP-1 market is projected to exceed $100B+ by the early 2030s, and Lilly is positioned as the category leader
On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List
Oral formulations promise broader accessibility but require entirely different production and packaging workflows